Emergent Biosolutions (EBS) : During the past 4 weeks, traders have been relatively bearish on Emergent Biosolutions (EBS), hence the stock is down -14.7% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -9.82% relative to the S&P 500. The 4-week change in the price of the stock is -13.82% and the stock has fallen -9.77% in the past 1 week.
The stock has recorded a 20-day Moving Average of 13.69% and the 50-Day Moving Average is 20.21%. Emergent Biosolutions (NYSE:EBS): On Fridays trading session , Opening price of the stock was $27.43 with an intraday high of $27.43. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $26.76. However, the stock managed to close at $26.87, a loss of 2.64% for the day. On the previous day, the stock had closed at $27.6. The total traded volume of the day was 850,255 shares.
The company Insiders own 17.2% of Emergent Biosolutions shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -3.33% . Institutional Investors own 86.76% of Emergent Biosolutions shares. During last six month period, the net percent change held by insiders has seen a change of -9.37%. Also, Equity Analysts at the Brokerage Firm, JP Morgan, maintains their rating on the shares of Emergent Biosolutions (NYSE:EBS). JP Morgan has a Overweight rating on the shares. As per the latest research report, the brokerage house lowers the price target to $36 per share from a prior target of $45. The rating by the firm was issued on August 5, 2016.
Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and Governments to address medical needs and emerging health threats. The Companys two operating divisions include Biodefense and Biosciences. The Companys Biodefense division is a pharmaceutical business focused on countermeasures that address CBRNE (Chemical, Biological, Radiological, Nuclear and Explosives) threats. The Biodefense divisions marketed products are BioThrax; BAT; Anthrasil; VIGIV, and RSDL. The Biodefense division investigational stage product candidates include NuThrax, PreviThrax, GC-072 and other biodefense product candidates. The Biosciences divisions marketed products are WinRho SDF, HepaGam B, VARIZIG and episil. The Biosciences division investigational stage product candidates include IXINITY, ES414 and otlertuzumab.